Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06340243
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-01
First Post:
2024-03-22
Brief Title:
Risk Adapted Therapy of Hodgkin Lymphoma in Upper Egypt
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Risk Adapted Therapy of Hodgkin Lymphoma in Upper Egypt
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
determine if radiotherapy could be safely omitted for early hodgkin lymphoma responder patients without compromising outcome
Detailed Description:
Hodgkins lymphoma accounts for around 40 of all pediatric lymphomas and is the most prevalent cancer among adolescents and young adults With combinations of chemotherapy and radiation Hodgkins lymphoma is roughly 80 curable placing it among the most treatable cancers Since the introduction of combination chemotherapy treatments 20 years ago the prognosis for children with Hodgkins lymphoma has improved The treatment is mostly influenced by the stage of the disease at diagnosis histology existence of B-symptoms and the presence of bulky disease Nonetheless 20 of patients do not achieve long-term remission and around 20 experience treatment-related side effects such as secondary malignancies infertility cardiovascular disease and organ malfunction following chemo-radiation Studies of long-term therapy side effects were made possible by the significant number of survivors The goal of therapy optimization protocols for pediatric patients with Hodgkins lymphoma is to maintain excellent tumor control while limiting adverse effects and long-term consequences It is critical to stratify patients based on reliable prognostic factors at presentation and according to the rapidity of response into low-risk LR patients who would benefit from less aggressive therapy avoiding unnecessary toxic side effects and high-risk HR patients who should be subjected to intensified therapy to reduce the rate of treatment failures and relapses
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None